The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Glucagon Injectable-Global Market Insights and Sales Trends 2024
Synopsis
The global Glucagon Injectable market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Glucagon Injectable in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others, are propelling Glucagon Injectable market. Children, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Adults segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Glucagon Injectable, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Glucagon Injectable market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Glucagon Injectable market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Glucagon Injectable sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Glucagon Injectable covered in this report include Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, Novo Nordisk A/S, ILS.Inc, Amphastar Pharmaceuticals Inc., Lilly USA, LLC, Zealand Pharma A/S. and Avalon Pharma Pvt. Ltd., etc.
The global Glucagon Injectable market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Fresenius SE & Co. KGaA
Xeris Pharmaceuticals Inc
Novo Nordisk A/S
ILS.Inc
Amphastar Pharmaceuticals Inc.
Lilly USA, LLC
Zealand Pharma A/S.
Avalon Pharma Pvt. Ltd.
Global Glucagon Injectable market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Glucagon Injectable market, Segment by Type:
Children
Adults
Global Glucagon Injectable market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Glucagon Injectable manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Glucagon Injectable in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Glucagon Injectable market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Glucagon Injectable in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others, are propelling Glucagon Injectable market. Children, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Adults segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Glucagon Injectable, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Glucagon Injectable market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Glucagon Injectable market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Glucagon Injectable sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Glucagon Injectable covered in this report include Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, Novo Nordisk A/S, ILS.Inc, Amphastar Pharmaceuticals Inc., Lilly USA, LLC, Zealand Pharma A/S. and Avalon Pharma Pvt. Ltd., etc.
The global Glucagon Injectable market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Fresenius SE & Co. KGaA
Xeris Pharmaceuticals Inc
Novo Nordisk A/S
ILS.Inc
Amphastar Pharmaceuticals Inc.
Lilly USA, LLC
Zealand Pharma A/S.
Avalon Pharma Pvt. Ltd.
Global Glucagon Injectable market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Glucagon Injectable market, Segment by Type:
Children
Adults
Global Glucagon Injectable market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Glucagon Injectable manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Glucagon Injectable in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Glucagon Injectable Market Overview
1.1 Glucagon Injectable Product Overview
1.2 Glucagon Injectable Market Segment by Type
1.2.1 Children
1.2.2 Adults
1.3 Global Glucagon Injectable Market Size by Type
1.3.1 Global Glucagon Injectable Market Size Overview by Type (2018-2029)
1.3.2 Global Glucagon Injectable Historic Market Size Review by Type (2018-2023)
1.3.3 Global Glucagon Injectable Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Glucagon Injectable Sales Breakdown by Type (2018-2023)
1.4.2 Europe Glucagon Injectable Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Glucagon Injectable Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Glucagon Injectable Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Glucagon Injectable Sales Breakdown by Type (2018-2023)
2 Global Glucagon Injectable Market Competition by Company
2.1 Global Top Players by Glucagon Injectable Sales (2018-2023)
2.2 Global Top Players by Glucagon Injectable Revenue (2018-2023)
2.3 Global Top Players by Glucagon Injectable Price (2018-2023)
2.4 Global Top Manufacturers Glucagon Injectable Manufacturing Base Distribution, Sales Area, Product Type
2.5 Glucagon Injectable Market Competitive Situation and Trends
2.5.1 Glucagon Injectable Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Glucagon Injectable Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Glucagon Injectable as of 2022)
2.7 Date of Key Manufacturers Enter into Glucagon Injectable Market
2.8 Key Manufacturers Glucagon Injectable Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Glucagon Injectable Status and Outlook by Region
3.1 Global Glucagon Injectable Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Glucagon Injectable Historic Market Size by Region
3.2.1 Global Glucagon Injectable Sales in Volume by Region (2018-2023)
3.2.2 Global Glucagon Injectable Sales in Value by Region (2018-2023)
3.2.3 Global Glucagon Injectable Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Glucagon Injectable Forecasted Market Size by Region
3.3.1 Global Glucagon Injectable Sales in Volume by Region (2024-2029)
3.3.2 Global Glucagon Injectable Sales in Value by Region (2024-2029)
3.3.3 Global Glucagon Injectable Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Glucagon Injectable by Application
4.1 Glucagon Injectable Market Segment by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.1.4 Others
4.2 Global Glucagon Injectable Market Size by Application
4.2.1 Global Glucagon Injectable Market Size Overview by Application (2018-2029)
4.2.2 Global Glucagon Injectable Historic Market Size Review by Application (2018-2023)
4.2.3 Global Glucagon Injectable Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Glucagon Injectable Sales Breakdown by Application (2018-2023)
4.3.2 Europe Glucagon Injectable Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Glucagon Injectable Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Glucagon Injectable Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Glucagon Injectable Sales Breakdown by Application (2018-2023)
5 North America Glucagon Injectable by Country
5.1 North America Glucagon Injectable Historic Market Size by Country
5.1.1 North America Glucagon Injectable Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Glucagon Injectable Sales in Volume by Country (2018-2023)
5.1.3 North America Glucagon Injectable Sales in Value by Country (2018-2023)
5.2 North America Glucagon Injectable Forecasted Market Size by Country
5.2.1 North America Glucagon Injectable Sales in Volume by Country (2024-2029)
5.2.2 North America Glucagon Injectable Sales in Value by Country (2024-2029)
6 Europe Glucagon Injectable by Country
6.1 Europe Glucagon Injectable Historic Market Size by Country
6.1.1 Europe Glucagon Injectable Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Glucagon Injectable Sales in Volume by Country (2018-2023)
6.1.3 Europe Glucagon Injectable Sales in Value by Country (2018-2023)
6.2 Europe Glucagon Injectable Forecasted Market Size by Country
6.2.1 Europe Glucagon Injectable Sales in Volume by Country (2024-2029)
6.2.2 Europe Glucagon Injectable Sales in Value by Country (2024-2029)
7 Asia-Pacific Glucagon Injectable by Region
7.1 Asia-Pacific Glucagon Injectable Historic Market Size by Region
7.1.1 Asia-Pacific Glucagon Injectable Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Glucagon Injectable Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Glucagon Injectable Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Glucagon Injectable Forecasted Market Size by Region
7.2.1 Asia-Pacific Glucagon Injectable Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Glucagon Injectable Sales in Value by Region (2024-2029)
8 Latin America Glucagon Injectable by Country
8.1 Latin America Glucagon Injectable Historic Market Size by Country
8.1.1 Latin America Glucagon Injectable Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Glucagon Injectable Sales in Volume by Country (2018-2023)
8.1.3 Latin America Glucagon Injectable Sales in Value by Country (2018-2023)
8.2 Latin America Glucagon Injectable Forecasted Market Size by Country
8.2.1 Latin America Glucagon Injectable Sales in Volume by Country (2024-2029)
8.2.2 Latin America Glucagon Injectable Sales in Value by Country (2024-2029)
9 Middle East and Africa Glucagon Injectable by Country
9.1 Middle East and Africa Glucagon Injectable Historic Market Size by Country
9.1.1 Middle East and Africa Glucagon Injectable Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Glucagon Injectable Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Glucagon Injectable Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Glucagon Injectable Forecasted Market Size by Country
9.2.1 Middle East and Africa Glucagon Injectable Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Glucagon Injectable Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Fresenius SE & Co. KGaA
10.1.1 Fresenius SE & Co. KGaA Company Information
10.1.2 Fresenius SE & Co. KGaA Introduction and Business Overview
10.1.3 Fresenius SE & Co. KGaA Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Fresenius SE & Co. KGaA Glucagon Injectable Products Offered
10.1.5 Fresenius SE & Co. KGaA Recent Development
10.2 Xeris Pharmaceuticals Inc
10.2.1 Xeris Pharmaceuticals Inc Company Information
10.2.2 Xeris Pharmaceuticals Inc Introduction and Business Overview
10.2.3 Xeris Pharmaceuticals Inc Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Xeris Pharmaceuticals Inc Glucagon Injectable Products Offered
10.2.5 Xeris Pharmaceuticals Inc Recent Development
10.3 Novo Nordisk A/S
10.3.1 Novo Nordisk A/S Company Information
10.3.2 Novo Nordisk A/S Introduction and Business Overview
10.3.3 Novo Nordisk A/S Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novo Nordisk A/S Glucagon Injectable Products Offered
10.3.5 Novo Nordisk A/S Recent Development
10.4 ILS.Inc
10.4.1 ILS.Inc Company Information
10.4.2 ILS.Inc Introduction and Business Overview
10.4.3 ILS.Inc Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.4.4 ILS.Inc Glucagon Injectable Products Offered
10.4.5 ILS.Inc Recent Development
10.5 Amphastar Pharmaceuticals Inc.
10.5.1 Amphastar Pharmaceuticals Inc. Company Information
10.5.2 Amphastar Pharmaceuticals Inc. Introduction and Business Overview
10.5.3 Amphastar Pharmaceuticals Inc. Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Amphastar Pharmaceuticals Inc. Glucagon Injectable Products Offered
10.5.5 Amphastar Pharmaceuticals Inc. Recent Development
10.6 Lilly USA, LLC
10.6.1 Lilly USA, LLC Company Information
10.6.2 Lilly USA, LLC Introduction and Business Overview
10.6.3 Lilly USA, LLC Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Lilly USA, LLC Glucagon Injectable Products Offered
10.6.5 Lilly USA, LLC Recent Development
10.7 Zealand Pharma A/S.
10.7.1 Zealand Pharma A/S. Company Information
10.7.2 Zealand Pharma A/S. Introduction and Business Overview
10.7.3 Zealand Pharma A/S. Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Zealand Pharma A/S. Glucagon Injectable Products Offered
10.7.5 Zealand Pharma A/S. Recent Development
10.8 Avalon Pharma Pvt. Ltd.
10.8.1 Avalon Pharma Pvt. Ltd. Company Information
10.8.2 Avalon Pharma Pvt. Ltd. Introduction and Business Overview
10.8.3 Avalon Pharma Pvt. Ltd. Glucagon Injectable Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Avalon Pharma Pvt. Ltd. Glucagon Injectable Products Offered
10.8.5 Avalon Pharma Pvt. Ltd. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Glucagon Injectable Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Glucagon Injectable Industrial Chain Analysis
11.4 Glucagon Injectable Market Dynamics
11.4.1 Glucagon Injectable Industry Trends
11.4.2 Glucagon Injectable Market Drivers
11.4.3 Glucagon Injectable Market Challenges
11.4.4 Glucagon Injectable Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Glucagon Injectable Distributors
12.3 Glucagon Injectable Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
